Limbrel Capsules by Primus Pharmaceuticals: FDA Advisory – Linked to Potentially Life-Threatening Health Problems

In total, the FDA has received 194 adverse event reports regarding Limbrel, of those, 57 of the cases contained sufficient information to analyze in detail whether Limbrel was associated with an adverse event; 30 of these contained sufficient information to use the Council for International Organizations of Medical Sciences (CIOMS) causality assessment method to determine the likelihood that an association between the consumption of Limbrel and the adverse events reported exists.

[...]

The ‘Price Savings’ of Drug Importation— Unboxing the Myth

Wayne Winegarden and Nouran Ghana’s editorial was published in Inside Sources on November 15, 2017. In it, they take a hard look at the supposed “price savings” of drug importation and find that the promises do not live up to what would happen. They believe that Americans deserve a better solution than plundering the drug supply of a neighboring country…

[...]

Proposed Bill Could Fuel the Opioid Epidemic

George M. Karavetsos’ editorial was published in The Hill on October 30, 2017. George M. Karavetsos is a partner with the global law firm DLA Piper. He formerly served as the director of the U.S. Food and Drug Administration’s Office of Criminal Investigations and chief of the Narcotics Section and the executive assistant U.S. attorney in the Southern District of Florida…

[...]